The Next Quarter Podcast - Episode 8 - Ian Coyne & Joe Stringer

Joe Stringer – ex‑Big Four health partner turned investor, operator, and board member – joins Ian to look ahead to 2050. Joe argues we’re entering an era of cost collapse and mass‑market adoption driven by AI, automation, and consumer demand, with health systems being dragged along rather than leading. We cover the implications for primary care, drug development, clinical trials, wellness, and where the best investment opportunities lie as AI capacity collides with the “real world.” Joe’s moonshot isn’t a new gadget – it’s rapid adoption at scale.

Highlights:

• Joe Stringer – ex‑Big Four health partner turned investor, operator, and board member – joins Ian to look ahead to 2050. Joe argues we’re entering an era of cost collapse and mass‑market adoption driven by AI, automation, and consumer demand, with health systems being dragged along rather than leading. We cover the implications for primary care, drug development, clinical trials, wellness, and where the best investment opportunities lie as AI capacity collides with the “real world.” Joe’s moonshot isn’t a new gadget – it’s rapid adoption at scale.
• Joe’s path in brief: Nearly three decades across health and life sciences; partner in EY’s health practice; co‑founded a health tech VC fund later acquired by Octopus Ventures; now a portfolio career spanning investing, operating, and board roles.
• Where change comes from by 2050: AI delivers dramatic efficiency gains (“cost collapse”) across health and life sciences; the debate shifts from if to how fast and who benefits.
• Health systems vs. the market: Adoption is being pushed by consumers and suppliers; health systems are too constrained to drive change and will be pulled along.
• AI’s near‑term shockwaves: Rapid progress from foundational AI players and the prospect of AI handling a significant share of primary‑care‑type demand – raising opportunities and risks for incumbents.
• Consumerization & wellness: Preventive, self‑directed health becomes mainstream; people spend more out‑of‑pocket on sleep, movement, weight, stress, and diagnostics; mass‑market models matter more than niche offerings.
• GLP‑1s as a wake‑up call: Blockbuster weight‑management drugs spotlight the commercial and clinical potential of prevention – and signal more lifestyle‑impacting therapies to come.
• Where investment gets interesting: The edge where AI capacity meets the physical world – wet labs, clinical trials, diagnostics, and care delivery – creating hybrid models that feel seamless to consumers.
• Drug development re‑wired: From autonomous labs to decentralized clinical trials and AI companies moving deeper into biopharma stacks, timelines and economics are being re‑set.
• Clinical trials in your chat window: A future where conversational AI routes suitable patients directly into nearby studies – shrinking timelines and broadening access.
• System impact: As consumers grow used to instant, low‑cost, personalized answers, real‑world services must catch up – or face a widening expectation gap.
• Moonshot: Not a new technology but mass adoption – the sector’s true “handbrake off” moment.
• Personal note: Early experiences observing surgery cemented Joe’s motivation: use innovation to help people, not just chase metrics.

The Next Quarter is brought to you by Coulter Partners, the leadership advisory and executive search firm building teams that change the world.